论文部分内容阅读
目的探讨小剂量尿激酶联合克林澳对频发短暂性脑缺血发作(TIA)的临床疗效。方法100例频发TIA患者随机分为对照组和治疗组。对照组采用常规治疗,治疗组在常规治疗基础上采用小剂量尿激酶和克林澳治疗。结果治疗组治疗后24h、3d内TIA发作控制率分别为72%和92%,均明显高于对照组(40%和68%)P<0.01。结论小剂量尿激酶联合克林澳对频发TIA疗效显著,且安全可靠,值得临床推广应用。
Objective To investigate the clinical efficacy of low-dose urokinase combined with Kelianao on patients with frequent transient ischemic attack (TIA). Methods One hundred patients with frequent TIA were randomly divided into control group and treatment group. The control group with conventional treatment, the treatment group on the basis of conventional treatment with low-dose urokinase and Kelin O treatment. Results The control rates of TIA in treatment group were 72% and 92% after 24h and 3d respectively, which were significantly higher than those in control group (40% and 68%, P <0.01). Conclusion Low-dose urokinase combined with Kelin O has a significant effect on frequent TIA and is safe and reliable, which is worthy of clinical application.